Yoshimasa Hoshikawa Selected Research

Non-Erosive Reflux Disease

1/2022	Determinants of reflux perception in patients with non-erosive reflux disease who have reflux-related symptoms on potassium-competitive acid blocker therapy.
10/2021	Saliva secretion is reduced in proton pump inhibitor-responsive non-erosive reflux disease patients.
1/2021	Prevalence of behavioral disorders in patients with vonoprazan-refractory reflux symptoms.
1/2021	Relationship between gastroesophageal reflux disease (GERD) and constipation: laxative use is common in GERD patients.
1/2019	Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease.
1/2018	Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
1/2017	Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshimasa Hoshikawa Research Topics

Disease

7	Peptic Esophagitis (Reflux Esophagitis) 01/2022 - 01/2017
7	Non-Erosive Reflux Disease 01/2022 - 01/2017
5	Gastroesophageal Reflux (GERD) 03/2022 - 06/2018
3	Heartburn (Pyrosis) 03/2022 - 01/2020
3	Dyspepsia (Indigestion) 03/2022 - 05/2021
2	Eructation (Eructations) 01/2022 - 01/2021
2	Hypersensitivity (Allergy) 05/2021 - 01/2021
2	Infections 01/2020 - 01/2017
1	Constipation 01/2021
1	Rumination Syndrome (Rumination Disorder) 01/2021
1	Hiatal Hernia 01/2020
1	Pathologic Constriction (Stenosis) 01/2020
1	Atrophy 01/2020
1	Kyphosis 01/2020
1	Hemorrhage 01/2020

Drug/Important Bio-Agent (IBA)

9	Proton Pump InhibitorsIBA 10/2021 - 01/2017
7	AcidsIBA 01/2022 - 01/2017
5	1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamineIBA 01/2020 - 01/2017
3	PotassiumIBA 01/2022 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2022 - 05/2021
2	Epidermal Growth Factor (EGF)IBA 01/2022 - 01/2021
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 03/2022
1	liu-jun-zi-tangIBA 03/2022
1	LaxativesIBA 01/2021
1	beta-Aminoethyl Isothiourea (AET)IBA 01/2020
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2020
1	GastrinsIBA 10/2019
1	TabletsIBA 01/2019

Therapy/Procedure

6	Therapeutics 01/2022 - 01/2018